Medulloblastoma: clinicopathologic evaluation of 42 pediatric cases

[1]  A. Tan,et al.  Epidemiology, management and treatment outcome of medulloblastoma in singapore. , 2007, Annals of the Academy of Medicine, Singapore.

[2]  R. Packer.  Progress and Challenges in Childhood Brain Tumors , 2005, Journal of Neuro-Oncology.

[3]  C. Sarkar,et al.  Are Childhood and Adult Medulloblastomas Different? A Comparative Study of Clinicopathological Features, Proliferation Index and Apoptotic Index , 2002, Journal of Neuro-Oncology.

[4]  F. Kayaselçuk,et al.  PCNA and Ki-67 in Central Nervous System Tumors: Correlation with the Histological Type and Grade , 2002, Journal of Neuro-Oncology.

[5]  J. Montebello,et al.  Intense P53 Staining is a Valuable Prognostic Indicator for Poor Prognosis in Medulloblastoma/central Nervous System Primitive Neuroectodermal Tumors , 2001, Journal of Neuro-Oncology.

[6]  R. Miralbell,et al.  Pediatric Medulloblastoma: Prognostic Value of p53, bcl-2, Mib-1, and Microvessel Density , 2004, Journal of Neuro-Oncology.

[7]  M. Edwards,et al.  Comparison of bromodeoxyuridine uptake and MIB 1 immunoreactivity in medulloblastomas determined with single and double immunohistochemical staining methods , 1996, Journal of Neuro-Oncology.

[8]  A. Chiò,et al.  Tumor cell proliferation and apoptosis in medulloblastoma , 2004, Acta Neuropathologica.

[9]  I. Diamantis,et al.  Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material , 2004, Acta Neuropathologica.

[10]  J. Plese,et al.  Medulloblastoma: evaluation of proliferative index by monoclonal antibody Mib-1, its prognostic correlation and therapeutic implications. , 2003, Arquivos de neuro-psiquiatria.

[11]  L. Rorke,et al.  Prognostic significance of Ki-67 (MIB-1) proliferation index in childhood primitive neuroectodermal tumors of the central nervous system. , 2001, Medical and pediatric oncology.

[12]  D. Nam,et al.  The effect of isochromosome 17q presence, proliferative and apoptotic indices, expression of c-erbB-2, bcl-2 and p53 proteins on the prognosis of medulloblastoma. , 2000, Journal of Korean medical science.

[13]  L. Rorke,et al.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Rorke,et al.  Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). , 1996, International journal of radiation oncology, biology, physics.

[15]  I. Pollack.  Brain tumors in children. , 1994, The New England journal of medicine.

[16]  V. Jay,et al.  Cell kinetic analysis in pediatric brain and spinal tumors: a study of 117 cases with Ki-67 quantitation and flow cytometry. , 1994, Pediatric pathology.

[17]  J. Lunec,et al.  p53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis. , 1993, British Journal of Cancer.

[18]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.

[19]  M. Prados,et al.  Cell kinetics of medulloblastomas , 1992, Cancer.

[20]  B. Scheithauer,et al.  Medulloblastoma--prognostic factors and outcome of treatment: review of the Mayo Clinic experience. , 1990, Mayo Clinic proceedings.